Table 1. Effects of VHL mutations on... | Rockefeller University Press

Table 1.

Effects of VHL mutations on VCAM-1 expression levels and its association with clinicopathologic characteristics in human ccRCCs

VHL alteration	n	VCAM-1 levels	P	Clinicopathologic characteristics		n	VCAM-1 levels	P^{^a}
Missense	32	2.622	0.739	Tumor stage	I + II	12	2.943	0.613
					III + IV	20	1.933
				Tumor grade	1 + 2	22	2.943	0.223
					3 + 4	10	1.484
				Tumor size	≤7	19	3.042	0.173
					7.1≥	13	1.775
				Microvascular invasion	neg	19	2.846	0.863
					pos	13	1.775
				Symptom presentation	neg	12	3.577	0.018
					pos	20	1.225
Nonmissense	95	2.099		Tumor stage	I + II	55	2.481	0.010
					III + IV	40	1.562
				Tumor grade	1 + 2	70	2.309	0.001
					3 + 4	25	1.336
				Tumor size	≤7	77	2.250	0.118
					7.1≥	18	1.492
				Microvascular invasion	neg	57	2.524	0.009
					pos	38	1.650
				Symptom presentation	neg	57	2.481	0.004
					pos	38	1.588

VHL alteration	n	VCAM-1 levels	P	Clinicopathologic characteristics		n	VCAM-1 levels	P^{^a}
Missense	32	2.622	0.739	Tumor stage	I + II	12	2.943	0.613
					III + IV	20	1.933
				Tumor grade	1 + 2	22	2.943	0.223
					3 + 4	10	1.484
				Tumor size	≤7	19	3.042	0.173
					7.1≥	13	1.775
				Microvascular invasion	neg	19	2.846	0.863
					pos	13	1.775
				Symptom presentation	neg	12	3.577	0.018
					pos	20	1.225
Nonmissense	95	2.099		Tumor stage	I + II	55	2.481	0.010
					III + IV	40	1.562
				Tumor grade	1 + 2	70	2.309	0.001
					3 + 4	25	1.336
				Tumor size	≤7	77	2.250	0.118
					7.1≥	18	1.492
				Microvascular invasion	neg	57	2.524	0.009
					pos	38	1.650
				Symptom presentation	neg	57	2.481	0.004
					pos	38	1.588

Abbreviations used: neg, negative; pos, positive.

Mann-Whitney U test was used.